NASDAQ:PRPOPrecipio Stock Price, Forecast & News

Precipio's stock was trading at $1.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PRPO stock has increased by 170.9% and is now trading at $3.17.
View which stocks have been most impacted by COVID-19.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precipio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Precipio.

Precipio is scheduled to release its next quarterly earnings announcement on Monday, August 17th 2020.
View our earnings forecast for Precipio.

Precipio (NASDAQ:PRPO) released its quarterly earnings results on Thursday, August, 23rd. The biotechnology company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of $1.93 by $2.08. The biotechnology company earned $0.82 million during the quarter. Precipio had a negative return on equity of 109.58% and a negative net margin of 407.60%.
View Precipio's earnings history.

Shares of Precipio reverse split on Tuesday, June 6th 2017. The 1-30 reverse split was announced on Thursday, May 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Precipio stock prior to the reverse split would have 3 shares after the split.

1 brokerages have issued 1 year target prices for Precipio's shares. Their forecasts range from $2.00 to $2.00. On average, they expect Precipio's stock price to reach $2.00 in the next twelve months. This suggests that the stock has a possible downside of 36.9%.
View analysts' price targets for Precipio.

Press coverage about PRPO stock has trended somewhat negative on Friday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Precipio earned a daily sentiment score of -1.8 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Precipio.

Some companies that are related to Precipio include Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT), BioNano Genomics (BNGO), HTG Molecular Diagnostics (HTGM), Aethlon Medical (AEMD), Scientific Industries (SCND), Pressure Biosciences (PBIO), Arrayit (ARYC) and PositiveID (PSID).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Precipio investors own include Portola Pharmaceuticals (PTLA), Biocept (BIOC), Jaguar Health (JAGX), Heat Biologics (HTBX), Inpixon (INPX), MannKind (MNKD), Ibio (IBIO), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV) and Achieve Life Sciences (ACHV).

Precipio trades on the NASDAQ under the ticker symbol "PRPO."

Shares of PRPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PRPO stock can currently be purchased for approximately $3.17.

Precipio has a market capitalization of $46.34 million and generates $3.13 million in revenue each year. Precipio employs 42 workers across the globe.

The official website for Precipio is www.precipiodx.com.

Precipio's mailing address is 4 Science Park, New Haven CT, 06511. The biotechnology company can be reached via phone at 203-787-7888 or via email at [email protected]